Is Streptokinase Safe During Menses?

Simel, David L.

doi:10.1001/archinte.1984.00350160211035

Arch Intern Med

1984

DOI: 10.1001/archinte.1984.00350160211035

|View full text |Cite

Is Streptokinase Safe During Menses?

David L. Simel¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1985

2002

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is little literature regarding the safety of thrombolysis during menstruation, and those cases reported are confined to cardiac and peripheral vascular disease, in which case most patients have received thrombolytics in conjunction with anticoagulants. [1][2][3][4][5][6][7][8][9] Of the 25 cases reported to date, only 2 have required transfusion, and no serious sequelae have occurred.…”

mentioning

confidence: 99%

Safety of Tissue Plasminogen Activator for Acute Stroke in Menstruating Women

Wein

Hickenbottom

Morgenstern

et al. 2002

Stroke

View full text Add to dashboard Cite

Background— Menses is a theoretical contraindication to intravenous tissue plasminogen activator (tPA) treatment. We sought to establish the safety of intravenous tPA in the treatment of acute ischemic stroke in women who are actively menstruating. Summary of Report— We provide a case report and review of the National Institute of Neurological Disorders and Stroke (NINDS) database for women coded as actively menstruating. Nine subjects were coded as actively menstruating in the NINDS trial (4 placebo and 5 in the treatment). One subject in the treatment group who had a 1-year history of dysfunctional uterine bleeding required emergent uterine artery ligation. We also report a case of a woman requiring transfusion after intravenous tPA administration for acute ischemic stroke. Conclusions— Intravenous tPA may be administered relatively safely in women who are menstruating and should be used with caution in women with a history of dysfunctional uterine bleeding. Potential patients should be advised that they might require transfusion for increased menstrual flow.

show abstract

mentioning

confidence: 99%

Safety of Tissue Plasminogen Activator for Acute Stroke in Menstruating Women

Wein

Hickenbottom

Morgenstern

et al. 2002

Stroke

View full text Add to dashboard Cite

show abstract

Safety of thrombolytic therapy in normally menstruating women with acute myocardial infarction

Lanter

Jennings

Roberts

et al. 1994

The American Journal of Cardiology

View full text Add to dashboard Cite

Treating menstruating women with thrombolytic therapy: Insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial

Karnash

Granger

White

et al. 1995

Journal of the American College of Cardiology

View full text Add to dashboard Cite

Although there was no statistically significant increase in bleeding risk during menstruation, this fact may be a result of low statistical power rather than a lack of effect. Thus, the results suggest that there may be a clinically significant increase in the risk of moderate bleeding. Nevertheless, the GUSTO-I experience is consistent with the concept that the lifesaving benefit of thrombolytic therapy for acute myocardial infarction should generally not be withheld because of active menstruation.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Is Streptokinase Safe During Menses?

Cited by 5 publications

References 12 publications

Safety of Tissue Plasminogen Activator for Acute Stroke in Menstruating Women

Safety of Tissue Plasminogen Activator for Acute Stroke in Menstruating Women

Safety of thrombolytic therapy in normally menstruating women with acute myocardial infarction

Treating menstruating women with thrombolytic therapy: Insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial

Contact Info

Product

Resources

About